Oppenheimer & CO Inc Alector, Inc. Transaction History

Oppenheimer & CO Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$7.65 - $14.24 $45,135 - $84,016	-5,900 Reduced 24.48%	18,200 $185,000
Q2 2021 Aug 03, 2021	SELL	$15.5 - $22.48 $489,955 - $710,592	-31,610 Reduced 56.74%	24,100 $502,000
Q1 2021 May 10, 2021	SELL	$14.84 - $22.23 $17,808 - $26,676	-1,200 Reduced 2.11%	55,710 $1.12 Million
Q4 2020 Feb 11, 2021	SELL	$9.4 - $16.7 $869,706 - $1.55 Million	-92,522 Reduced 61.92%	56,910 $861,000
Q3 2020 Nov 13, 2020	BUY	$10.54 - $24.96 $223,447 - $529,152	21,200 Added 16.53%	149,432 $1.57 Million
Q2 2020 Aug 11, 2020	SELL	$21.87 - $33.11 $607,986 - $920,458	-27,800 Reduced 17.82%	128,232 $3.13 Million
Q1 2020 May 08, 2020	BUY	$16.25 - $35.28 $438,750 - $952,560	27,000 Added 20.93%	156,032 $3.77 Million
Q4 2019 Feb 07, 2020	BUY	$14.17 - $20.3 $921,900 - $1.32 Million	65,060 Added 101.7%	129,032 $2.22 Million
Q3 2019 Oct 31, 2019	BUY	$14.42 - $22.2 $17,304 - $26,640	1,200 Added 1.91%	63,972 $922,000
Q2 2019 Aug 09, 2019	BUY	$16.26 - $26.42 $1.02 Million - $1.66 Million	62,772 New	62,772 $1.19 Million

168

57.8M

146K

90.8K

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $159M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.